VolitionRXVNRX
Market Cap: $64.3M
About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Employees: 110
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
13% more funds holding
Funds holding: 24 [Q1] → 27 (+3) [Q2]
0.01% less ownership
Funds ownership: 9.65% [Q1] → 9.64% (-0.01%) [Q2]
19% less capital invested
Capital invested by funds: $6M [Q1] → $4.84M (-$1.16M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
EF Hutton Tim Moore 26% 1-year accuracy 14 / 53 met price target | 616%upside $5 | Buy Assumed | 26 Aug 2024 |
Financial journalist opinion
Based on 3 articles about VNRX published over the past 30 days